NASDAQ:INM InMed Pharmaceuticals Q3 2025 Earnings Report $2.98 -0.34 (-10.24%) As of 06/4/2025 04:00 PM Eastern ProfileEarnings History InMed Pharmaceuticals EPS ResultsActual EPS-$1.94Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInMed Pharmaceuticals Revenue ResultsActual Revenue$1.26 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AInMed Pharmaceuticals Announcement DetailsQuarterQ3 2025Date5/12/2025TimeAfter Market ClosesConference Call DateSunday, May 11, 2025Conference Call Time6:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) InMed Pharmaceuticals Earnings HeadlinesBest Cannabis Stocks To Follow Now - June 2ndJune 5 at 4:21 AM | americanbankingnews.comInMed Pharmaceuticals Board Reshuffle After Director ResignationFebruary 14, 2025 | tipranks.comThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.June 5, 2025 | Weiss Ratings (Ad)InMed Pharmaceuticals Second Quarter 2025 Earnings: US$3.65 loss per share (vs US$3.71 loss in 2Q 2024)February 14, 2025 | finance.yahoo.comInMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular DegenerationFebruary 3, 2025 | finanznachrichten.deInMed advances AMD treatment with promising IVT drug formulationFebruary 3, 2025 | msn.comSee More InMed Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like InMed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on InMed Pharmaceuticals and other key companies, straight to your email. Email Address About InMed PharmaceuticalsInMed Pharmaceuticals (NASDAQ:INM), a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.View InMed Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Ollie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns? Upcoming Earnings Oracle (6/11/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025)PepsiCo (7/10/2025)Bank of America (7/14/2025)JPMorgan Chase & Co. (7/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
